FDA Places Partial Clinical Hold on Zentalis’ Azenosertib Cancer Studies Following Two Sepsis Deaths

Zentalis Pharmaceuticals, azenosertib, FDA, partial clinical hold, cancer studies, sepsis deaths, WEE1 inhibitor, clinical trials, patient safety

The Future of Healthcare: Embracing Omnichannel Care for Seamless Patient Experience

Omnichannel care, Telehealth, Healthcare technology, Patient-centric care, Integrated healthcare delivery, Virtual care, In-person care, Healthcare innovation, Digital health, Healthcare trends